Cardionovum® is proud to announce a major milestone: For the approval by ANVISA, the Brazilian Health Regulatory Agency, of Aperto® OTW DCB for commercial use in Brazil. This approval enables Brazilian patients undergoing dialysis to benefit from a therapy that extends the lifespan of their arteriovenous fistulas, thereby improving both quality of life and treatment outcomes.

At EuroPCR 2025, Dr. Aloke Finn and Prof. Antonio Colombo discussed the under-recognized issue of particulate embolization after drug-coated balloon (DCB) angioplasty.

They clarified its distinction from traditional distal embolization and underscored its iatrogenic nature—originating from the device, not plaque or thrombus. The conversation highlighted that particle size, carrier type, and coating technology, particularly crystalline-like coatings, play key roles in downstream safety.

While not universally problematic, embolization may be relevant for specific patients or devices. They stressed the need to translate preclinical insights into clinical practice and to innovate DCB technologies that balance safety with efficacy.